Company profile for Revalesio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Revalesio is a clinical-stage pharmaceutical company committed to creating treatments for neurological diseases and conditions that lack adequate therapeutic options. Our therapies address cellular imbalances related to mitochondrial dysfunction and thereby modulate the immune response. They have been shown to protect neurons in models of chronic neurological diseases and improve recovery in acute neurological injury. We ar...
Revalesio is a clinical-stage pharmaceutical company committed to creating treatments for neurological diseases and conditions that lack adequate therapeutic options. Our therapies address cellular imbalances related to mitochondrial dysfunction and thereby modulate the immune response. They have been shown to protect neurons in models of chronic neurological diseases and improve recovery in acute neurological injury. We are partnering with internationally renowned scientists in biomedical research in a concerted effort to improve the lives of millions.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1202-1204 E D St Tacoma, WA 98421
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Natural Products Expo

Natural Products Expo

Not Confirmed

envelop Contact Supplier

Natural Products Expo

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/revalesio-to-present-findings-from-a-post-hoc-analysis-of-phase-2-rescue-trial-at-svin-2025-highlighting-rns60s-potential-to-shorten-hospital-stay-302619619.html

PR NEWSWIRE
19 Nov 2025

https://www.prnewswire.com/news-releases/revalesio-to-present-rns60-12-hour-data-from-the-phase-2-rescue-trial-in-acute-ischemic-stroke-at-world-stroke-congress-2025-302589710.html

PR NEWSWIRE
21 Oct 2025

https://www.prnewswire.com/news-releases/revalesio-receives-fda-fast-track-designation-for-rns60-for-the-treatment-of-acute-ischemic-stroke-302517694.html

PR NEWSWIRE
31 Jul 2025

https://www.prnewswire.com/news-releases/revalesio-announces-publication-of-rescue-phase-2-trial-results-evaluating-rns60-as-an-adjunctive-therapy-for-acute-ischemic-stroke-in-the-journal-stroke-302509320.html

PR NEWSWIRE
21 Jul 2025

https://www.prnewswire.com/news-releases/revalesio-to-present-phase-3-trial-design-and-post-hoc-analysis-of-phase-2-rescue-trial-of-rns60-in-acute-ischemic-stroke-at-the-snis-22nd-annual-meeting-302503947.html

PR NEWSWIRE
14 Jul 2025

https://www.prnewswire.com/news-releases/revalesio-presents-additional-analyses-from-the-phase-2-rescue-clinical-trial-for-rns60-in-acute-ischemic-stroke-302461333.html

PR NEWSWIRE
21 May 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty